Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bisoprolol + nebivolol (Clinical Hospital Center Zemun)
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a comparative clinical research context (specifically the BINEB trial) evaluating the echocardiographic effects of two distinct beta-blockers, bisoprolol and nebivolol. Bisoprolol is a highly selective beta-1 adrenergic receptor antagonist used to treat hypertension and heart failure by reducing heart rate and myocardial contractility. Nebivolol is a third-generation beta-blocker that combines high beta-1 selectivity with unique vasodilatory properties mediated by beta-3 adrenergic receptor agonism and the subsequent release of nitric oxide from the vascular endothelium. The Clinical Hospital Center Zemun conducted the BINEB study as a randomized, double-blind, crossover trial in healthy subjects to compare the acute hemodynamic and cardiac effects of single 5 mg doses of each agent. Both drugs are widely approved for the management of cardiovascular conditions including hypertension and chronic heart failure.
- Brand names
- ZebetaBystolicConcorNebiletMonocorBisoprolol Merck
- Other names
- Bisoprolol fumarateNebivolol hydrochloride
02
Targets
ADRB3 (β3)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on bisoprolol + nebivolol (Clinical Hospital Center Zemun).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bisoprolol + nebivolol (Clinical Hospital Center Zemun).